Publicaciones en las que colabora con Carmen de Mendoza (10)

2009

  1. Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 10, pp. 4153-4158

2008

  1. Association between tipranavir plasma levels and virological response in HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 24, Núm. 3, pp. 389-391

  2. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir

    Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785

  3. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822

2007

  1. Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 7, pp. 879-885

  2. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

2005

  1. Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity

    HIV Clinical Trials, Vol. 6, Núm. 4, pp. 197-202

2003

  1. Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure

    AIDS Research and Human Retroviruses, Vol. 19, Núm. 6, pp. 457-459

  2. Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations

    AIDS, Vol. 17, Núm. 3, pp. 442-444

2002

  1. Salvage treatment with lopinavir.ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families

    HIV Clinical Trials, Vol. 3, Núm. 4, pp. 304-309